Renal Clearable H-Dots Leveraging Ligand Complexation for Enhanced Active Tumor Targeting

Area of Science:

• Nanotechnology
• Biomedical Engineering
• Oncology

Background:

• Ligand conjugation to nanoparticles is a strategy for active tumor targeting.
• Conjugation can alter nanoparticle physicochemical properties, affecting biodistribution and pharmacokinetics.
• Ultrasmall nanocarriers are desirable for improved tumor penetration.

Purpose of the Study:

• To investigate enhanced active targeting efficiency by conjugating cyclic arginine-glycine-aspartic acid (cRGD) peptides onto ultrasmall H-dots.
• To assess if cRGD conjugation preserves the H-dot's physicochemical and pharmacokinetic properties.
• To evaluate the tumor-specific delivery and retention of cRGD-conjugated H-dots.

Main Methods:

• Integration of cRGD peptides onto ultrasmall H-dot nanocarriers.
• Assessment of cellular uptake via integrin α_vβ₃ receptors.
• Quantitative evaluation of active targeting efficacy using fluorescence imaging and histological analysis.
• Evaluation of cytotoxicity and pharmacokinetic profiles.

Main Results:

• cRGD/H-dots showed improved cellular uptake through integrin α_vβ₃.
• Active targeting efficacy was enhanced (two-fold increase, 1.2%ID/g) compared to unmodified H-dots.
• Physicochemical and pharmacokinetic attributes of H-dots were preserved.
• Negligible cytotoxicity was observed for cRGD/H-dots.

Conclusions:

• cRGD conjugation to H-dots enhances tumor targetability and retention.
• This strategy improves active targeting without compromising nanoparticle properties.
• The developed cRGD/H-dots maintain active renal clearance of unbound molecules.